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1. Introduction 
The biosynthesis of numerous secretory proteins 
and peptide hormones appears to proceed via higher 
molecular weight precursors [ 1-4]. These larger 
forms, elaborated on the rough-surfaced ndoplasmic 
reticulum [5,6], undergo several transformations, 
named processing, which generally lead to the 
unmasking of biologically active 'final' compounds. 
Biosynthetic evidence [7,8] for such a general 
scheme, derived from in vivo pulse chase experiments, 
seems to apply to the biogenesis of the neurophysins, 
neurohypophyseal hormone-associated proteins, 
synthesized by neurosecretory neurons of the magno- 
cellular system in the supraopticus and paraventricular 
nuclei of the hypothalamus. In the course of our 
biochemical pproach to the characterization f such 
putative pro-neurophysins wewere able to detect, 
using a radioimmunological assay, neurophysin-like 
materials with molecular weight '17 k' and ~ '20 k'. 
The possible plurifunctionality of the immunologically 
related high molecular forms of neurophysin solated 
from mouse hypothalamus extracts was tested. 
Besides this putative ' 17 k' pro-neurophysin, high 
molecular weight forms of materials immunologically 
related to somatostatin (somatotrope r leasing 
inhibitor factor: SRIF) could be found. We show 
evidence that the neurophysin-like and SRIF-like 
immunoreactivity are associated with distinct 
molecules and that the putative 'l 7 k' pro-neurophysin 
probably contains carbohydrate moieties. 
2. Materials and methods 
Phenylmethyl-sulfonylfluoride (PMSF), Trasylol, 
insoluble concanavalin A (Con A)-agarose, and 
~-methyl-D-mannoside were purchased from Sigma 
(St Louis). Triton X-100 was supplied by Calbiochem 
(San Diego). The antiserum A5 IV directed against 
neurophysin was a gift of Dr Legros (Liege) [9]. The 
antisomatostatin 3638 antiserum was provided by the 
URIA (Dr Dray) Institut Pasteur, Paris. 
All experiments were performed at 4°C. Mice 
hypothalami (50 fragments) were removed under a 
Nikon type 102 binocular immediately after sacrifice 
and homogenized with a Potter Elvejhem in 5 ml 
0.1 N HC1, 8 M urea, 5 mM PMSF, 130 units/ml 
Trasylol. The extract was frozen in liquid nitrogen 
and thawed (3 times), then centrifuged 1 h at 
100 000 × g in a SW 50 rotor (Beckman L5 50). The 
supernatant was filtered on a Bio-gel P-10 or a 
Sephadex G-50 column equilibrated and eluted with 
0.1 N HCOOH containing 0.1% Triton X-100, 
0.5 mM PMSF and 130 units/ml Trasylol. All fractions 
were tested by a radioimmunoassay procedure (RIA) 
using antisera directed against neurophysin (A5 IV) 
or somatostatin (3638). The free iodinated tracer was 
separated from the antibody-bound tracer by means 
of zyrconyl phosphate for neurophysin [10] and 
propanol precipitation for somatostatin. The insoluble 
concanavalin A column (Con A-agarose complex) 
was prepared as in [11]. The samples were dissolved 
in the Con A buffer (0.01 M Tris-HC1, 0.7 mM 
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MgC12, 1.0 mg/ml bovine serum albumin, 1.0 M NaC1, 
0.1% Triton X-100, pH 7.4) and layered on the 1 ml 
columns. After washing with 30 ml Con A buffer, the 
specifically bound material was eluted with 0.2 M 
a-methyl-D-mannoside in Con A buffer, followed by 
1 M a-methyl-D-mannoside in the same buffer. After 
this treatment, any material still bound to the column 
was eluted with 0.1 M acetic acid. All fractions were 
tested by the RIA procedure. 
3. Results 
The elution profile in f ig. lA indicates clearly that 
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to the 10 k mol. wt species (neurophysin) two other 
peaks (_~ '20 k'  and -~ '17 k')  can be detected. The 
relative amount of the _-> '20 k'  and ~- '17 k'  species 
was dependent largely upon the extraction procedure. 
When membrane centrifugation i isotonic sucrose 
buffer was performed before the 100 000 × g cen- 
trifugation, the => '20 k'  species appeared more 
intensely suggesting a membrane-mediated d grada- 
tion of  this high molecular weight form. In addition, 
the proportion o f '  17 k'  species increased significantly 
consecutive to protease inhibitor addition. The 
molecular weight homogeneity of this compound was 
demonstrated by further Bio-gel P-10 filtration after 
16 h exposure to 8 M urea [12] (fig.lB). This 
demonstrates that these forms of neurophysin-like 
material are not neurophysin aggregates or non- 
covalent polypept ide-neurophysin complexes. An 
analysis of the same hypothalamic extract for SRIF- 
like immunoreactivity showed a pattern suggesting 
multiple high molecular weight forms with a major 
component distinct from the '17 k' neurophysin-like 
peak (not shown). In order to obtain an improved 
separation of these components the same analysis 
was conducted on a Sephadex G-50 column. 
Figure 2A shows a pattern indicating three major 
immunoreactive components of molecular weight 
respectively evaluated to '15 k', '8 k'  and a com- 
pound co-eluting with somatostatin. The molecular 
weight homogeneity of these '15 k'  and '8 k'  species 
(fig.2B,2C) was established by the same procedure 
used for the '17 k'  putative proneurophysin after 
48 h exposure to urea. As can be observed on both 
Fig.1. Immunological evidence for high molecular weight 
forms ofneurophysin. (A) Gel filtration fractionation (Bio-gel 
P-10, 40 × 2.6 cm column in 0.1 N HCOOH containing 0.1% 
Triton X-100, 0.5 mM PMSF and 130 units/ml Trasylol) of 
the neurophysin-like immunoreactive material (as determined 
by RIA on each 1 ml eluted fraction) after extraction i
0.1 N HC1 containing 8 M urea, 5 mM PMSF, 130 units/ml 
Trasylol, of mouse hypothalami. The discrete immunoreactive 
peak eluted at the V o corresponds toa material >~ 20 k. (B) 
Gel filtration (Bio-gel P-10, 19 × 1.6 cm column in 0.1 N 
HCOOH containing 0,1% Triton X-100, 0.5 mM PMSF, 
130 units/ml Trasylol) of '17 k' species after a 16 h treat- 
ment in 8 M urea. Immunoreactive material was found only 
at the V e of the '17 k' species. The Bx/B o X I00 ratio 
represents he percentage of the antibody-bound [ 2s I ]neuro- 
physin tracer. 
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Fig.2. Immunological evidence for high molecular weight 
forms of somatostatin. (A) Gel fftitration fractionation 
(Sephadex G-50, 75 × 1.2 cm column in 0.1 N HCOOH 
containing 0.1% Triton X-100, 0.5 mM PMSF, 130 units/m1 
Trasylol) of the somatostatin-like material (as determined by 
RIA on each 1 ml eluted fraction) after extraction in 0.1 N 
HC1 containing 8 M urea, 5 mM PMSF, 130 units/ml Trasylol, 
of mouse hypothalami. (B) Gel filtration (Sephadex G-50, 
45 × 1.2 cm column in 0.1 N HCOOH containing 0.1% 
Triton X-100, 0.5 mM PMSF, 130 units/ml Trasylol) of the 
'15 k' species after a 48 h treatment in 8 M urea. The 
recovery of the total somatostatin immunoreactivity was 
> 90%. (C) Gel f'xltration (Sephadex G-50, 45 × 1.2 cm 
column in 0.1 N HCOOH containing 0.1% Triton X-100, 
0.5 mM PMSF, 130 units/ml Trasylol) of the '8 k' species 
after a 48 h treatment in 8 M urea. The recovery of the 
immunoreactive somatostatin-like material was 1> 90%. The 
Bx/B o X 100 ratio represents he percentage of the antibody- 
bound [a2SI]somatostatin tracer. 
f ig.2A,2B the '15 k '  peak reveals a shoulder  (-~ 10 k) 
possibly corresponding to an intermediary  form. 
The immunolog ica l  ident i ty  between the '17 k '  
neurophys in- l ike mater ia l  and neurophys in  on the one 
hand and of  these '15 k '  and '8 k '  somatostat in- l ike 
compounds  wi th  somatostat in  on the other  was 
establ ished by direct R IA  compet i t ion  assay. Dis- 
p lacement  curves parallel to the standard curve were 
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Fig.3. Immunological characterization f the '17 k' neuro- 
physin-like and '15 k' and '8 k' somatostatin-like materials. 
(A) Comparison of the cross reactivity of mouse neurophysin 
(o) and '17 k' species (e) as studied by RIA using antiserum 
(A5 IV serum obtained from Dr Legros) exhibiting no species 
specificity. (B) Comparison of the cross-reactivity of reference 
somatostatin (0) the '15 k' (e) and the '8 k' (e) species as 
studied by RIA using a somatostatin a tiserum 3638 and 
Tyr-N-somatostatin as tracer. 
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of the putative '17 k' pro-neurophysin a d '15 k' 
somatostatin-like material with trypsin (trypsin 
dilutions 1/100 or 1]1000; incubation at 37°C; 
10 min, 30 min, 60 min) only small molecular weight 
species, corresponding to degradation forms of 
neurophysin and somatostatin could be found, possi- 
bly suggesting that conversion of these high molecular 
weight forms of neurophysin-like and somatostatin- 
like material in final components i  not mediated by a 
trypsin-like cleavage. 
Glycosylation of biosynthetic precursors forms of 
secretory peptides has been shown [11,13,14] to be 
involved at various stages of the secretion process. 
Affinity chromatography onCon A-agarose might 
provide a simple mean of determining whether these 
high molecular weight forms of neurophysin or 
somatostatin were glycoproteins. The '15 k' SRIF 
like compound purified by Bio-gel P-10 column 
(fig.2B) were lyophylized, diluted in Con A buffer 
and analyzed on a column of Con A-agarose as in 
section 2. As shown in the fig.4A the '15 k' product 
was not bound to the affinity adsorbant and almost 
entirely eluted from the column by the washing 
buffer. In contrast a major part of the starting 
'neurophysin-like' material recovered as a '17 k' peak 
was found to be eluted from the affinity adsorbant 
only by 0.2 M a-methyl-D-mannoside, fig.4B, suggesting 
carbohydrate mediated interactions with the 
adsorbant. 
4. Discussion 
The above-reported observations reinforce and 
extend the previous findings from pulse-chase analysis 
by others [7,8,15] that neurophysin biosynthesis 
may occur via higher molecular weight precursors. In 
addition to the '17 k' form, we are able also to detect 
a =;> '20 k' species which seems to be relatively labile 
and could preferably be isolated as a product of 
in vitro translation of reticulum-bound polysomes 
from hypothalamic neurons. Iso-electricfocusing of 
the '17 k' species reveals ome heterogeneity on the 
basis of the net charge and suggests that two distinct 
high molecular weight forms of neurophysin are 
present [16,17] in keeping with the idea supporting 
that the two major neurophysins found in the mouse 
hypothalamo-neurohypophysis tract are synthesized 
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Fig.4. Affinity chromatography on a Con A agarose 
adsorbant. (A) The lyophylized '15 k' somatostatin-like 
material dissolved in 1 ml of the Con A buffer (0.01 M Tris- 
HC1, 1.0 M NaC1, 0.7 mM MgCI~, 0.1% Triton X-100, 1 mg/m] 
SAB, pH 7.4) was adsorbed on a Con A agarose column 
(1 ml total vol.) equihbrated in the same buffer. The column 
was washed with 30 ml Con A buffer (a) and eluted with 
10 ml 0.2 M a-methyl-D-mannoside in Con A buffer (b), 
followed by 10 ml 1 M c~-methyl-D-mannoside in Con A 
buffer (c). The column was then washed by 10 ml 0.1 M 
acetic acid (d). Immunoreactive material was determined by 
RIA on each 1 ml fraction. The recovery of immunoreactive 
somatostatin-like material was ~> 95%. (B) The lyophylized 
'17 k' neurophysin-like material dissolved in 1 ml Con A 
buffer was adsorbed and eluted from the column as described 
in fig.4A. The recovery of immunoreactive n urophysin-like 
material eluted by 0.2 M a-methyl-D-mannoside buffer was 
/> 90%. 
via two pro-neurophysins. Our observations also bring 
an additional element suggesting that the high 
molecular form of neurophysin is glycosylated. This 
suggests that the estimated molecular weight ('17 k') 
of this form is, possibly, not exact and remains to be 
determined by methods which are not impaired by 
the presence of carbohydrate moieties on the molecule 
[ 11 ]. The question of  possible common precursor 
molecules for the vasopressin-neurophysin and/or 
ocytocin-neurophysin pairs still remains open. 
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In situ observations of simultaneous positive 
reactions of supraoptic and paraventricular nuclei of  
rat hypothalamus with anti-SRIF and anti-neurophysin 
antibodies [18,19] might be taken as suggestive of 
common loci of synthesis, and eventually by reference 
to other plurifunctional pro-hormones [20,21 ],  of a 
common precursor molecule. Our analysis of the 
extract with anti-SRIF anti-serum delineates the 
presence of  multiple high molecular weight forms. 
But two sets of evidence suggest that SRIF-like and 
neurophysin-like species belong in two distinct 
families of molecules. These include: 
(i) The different elution profile; 
(ii) The absence of any detectable affinity of the 
'15 k '  SRIF-like form on the Con A adsorbant 
in contrast with the behaviour of the '17 k'  
neurophysin-like material. 
Of interest are the very recent observations made 
on the canine pancreas [22] describing high molecular 
weight forms (12 k and 3.5 k) of SRIF comparable 
with ours. Some apparent differences might be due to 
posttranslational modifications of products, resulting 
from different extraction procedures. 
More detailed biochemical analysis of those pro- 
hormones molecules, in progress in our laboratory, 
will permit to establish more definitive structural 
relationships between the putative precursors and 
secretory products. 
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